Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.01 USD | -5.50% | -6.24% | -56.89% |
Financials (USD)
Sales 2024 * | 13.01M | Sales 2025 * | 12.99M | Capitalization | 505M |
---|---|---|---|---|---|
Net income 2024 * | -224M | Net income 2025 * | -260M | EV / Sales 2024 * | 3.52 x |
Net cash position 2024 * | 459M | Net cash position 2025 * | 228M | EV / Sales 2025 * | 21.3 x |
P/E ratio 2024 * |
-2.24
x | P/E ratio 2025 * |
-2.11
x | Employees | 255 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.7% |
Latest transcript on Verve Therapeutics, Inc.
1 day | -5.50% | ||
1 week | -6.24% | ||
1 month | -20.92% | ||
3 months | -55.25% | ||
6 months | -61.72% | ||
Current year | -56.89% |
Managers | Title | Age | Since |
---|---|---|---|
Sekar Kathiresan
FOU | Founder | 52 | 17-12-31 |
Allison Dorval
DFI | Director of Finance/CFO | 48 | 21-11-28 |
Andrew Ashe
PSD | President | 57 | 18-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Burt Adelman
FOU | Founder | 71 | 17-12-31 |
Lonnel Coats
BRD | Director/Board Member | 58 | 22-08-07 |
Michael MacLean
BRD | Director/Board Member | 58 | 21-04-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
4.13% | 2 M€ | -25.75% | ||
3.54% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 6.01 | -5.50% | 1,604,714 |
24-05-09 | 6.36 | +4.61% | 1,956,209 |
24-05-08 | 6.08 | -1.30% | 1,464,270 |
24-05-07 | 6.16 | -3.90% | 888,521 |
24-05-06 | 6.41 | 0.00% | 812,274 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-56.89% | 505M | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- VERV Stock